What Urizia Treats: Main Uses and Benefits

Urizia is commonly used to help with moderate-to-severe Lower Urinary Tract Symptoms (LUTS) in adult men, targeting symptoms that create noticeable physiological strain and are relevant in conditions related to Benign Prostatic Hyperplasia (BPH). This combination therapy is applied in scenarios where additional management of discomfort is required due to the dual presence of bothersome storage and voiding symptoms and is relevant when symptoms persist despite other symptomatic management.

The medication helps address symptom clusters including the sudden, strong urge to urinate (urgency), excessive urination frequency, the need to wake up frequently at night (nocturia), a slow or weak urinary stream, and difficulty starting urination (hesitancy).

The therapy provides supportive relief across the co-existing LUTS components. It offers symptomatic relief that helps patients cope more steadily with difficult episodes and contributes to improved overall day-to-day comfort.

---

Quick Fact: Support for Mixed LUTS Symptoms The medication is typically used in men who experience both the bladder-related distress of urgency and frequency and the prostate-related issues of hesitancy and poor flow, when combined symptomatic support is appropriate.

---

Regulatory References

1. Summary of Product Characteristics (HPRA)

Who Can and Cannot Use Urizia?

Urizia is intended exclusively for Adult Males aged 18 years and over and is not for use in children, adolescents, or females, including those who are pregnant or breastfeeding. The official regulatory profile establishes clear contraindications and conditional use requirements based on the patient’s health status.

---

Contraindicated Populations

The medicine must not be used in patients with a history of Orthostatic Hypotension, Severe Hepatic Impairment (Child-Pugh C), or those undergoing Haemodialysis. It is also prohibited for patients with certain severe conditions, including Uncontrolled Narrow-Angle Glaucoma, Myasthenia Gravis, Urinary Retention, or Severe Gastrointestinal conditions such as Toxic Megacolon. Use with any other Alpha-1 Adrenoceptor Antagonist is also contraindicated.

---

Condition-Specific Restrictions

Use requires caution in patients with Severe Renal Impairment (creatinine clearance less than 30 mL/min) or Moderate Hepatic Impairment (Child-Pugh B). The medicine becomes contraindicated in these organ-impaired groups if a Strong CYP3A4 Inhibitor is taken concurrently. Physicians are cautioned against initiating therapy in patients who are scheduled for Cataract or Glaucoma Surgery.

Urizia is a combination product containing mirabegron and solifenacin. Its interaction profile is determined by the effects of both active ingredients on the body and on drug-metabolizing systems.

Pharmacokinetic Interactions

The mirabegron component is classified as a moderate inhibitor of the enzyme CYP2D6. Co-administration with medicines that are substrates of CYP2D6, such as Metoprolol and the antidepressant Desipramine, may increase the exposure of the co-administered drug, potentially requiring a dose adjustment, particularly for drugs with a narrow therapeutic index. Mirabegron also increases the plasma concentration of Digoxin, a P-glycoprotein (P-gp) substrate; patients starting this combination should be monitored for Digoxin levels.

Both mirabegron and solifenacin are metabolized by the enzyme CYP3A4. Therefore, co-administration with a strong CYP3A4 inhibitor, such as Ketoconazole, can significantly increase the systemic exposure of both Urizia components. Caution and possible dose reduction of Urizia are required when such combinations are necessary.

Pharmacodynamic and Condition-Specific Notes

The solifenacin component is an anticholinergic agent. Combining Urizia with other anticholinergic medicines used for overactive bladder may increase the risk of side effects like urinary retention and constipation due to additive effects. The product should be used with caution in patients with a history of QT prolongation or those taking medicines known to prolong the QT interval.

Urizia works by influencing defined biological systems through a specific mechanism of action. It is designed to modulate signaling activity in specific pathways at the molecular level, ultimately influencing the balance of activity within these biological pathways.

Selective Receptor Targeting

Urizia initiates its action by selectively engaging defined receptor systems within central and peripheral pathways. This primary interaction is an initial mechanistic step, determining which specific molecular cascade is subsequently engaged or suppressed.

Modulating Signal Transduction

Following binding, the drug operates within well-characterized molecular cascades to alter signaling dynamics. This process is relevant in systems where excessive mediator activity or heightened pathway activation dominates, altering the dynamics of cellular communication.

Influencing Physiological Responses

By modifying these early molecular steps, Urizia influences the regulation of defined physiological responses. This results in downstream changes in physiological parameters that contribute to the resultant physiological activity by reducing the duration or magnitude of excessive signaling on targeted systems.

How Urizia is Used

Urizia is administered according to a specific, standardized protocol for adult males. The fixed-dose combination contains Solifenacin 6 mg and Tamsulosin Hydrochloride 0.4 mg in a single film-coated tablet.

Administration Scope	General Guidelines
Route of Administration	The only approved method of administration is oral (by mouth).
Dosing Schedule & Frequency	The standard regimen is one tablet once daily (q.d.). This dose also represents the maximum recommended daily dose for this fixed-dose product.
Timing in Relation to Meals	The tablet must be taken with food or following the same meal each day to ensure consistent drug exposure and to maintain the pharmacological profile of the components.
Missed Dose Instructions	If a dose is missed, it should be taken at the next scheduled meal time on the same day. If a full day has passed, the missed dose should be skipped, and the regular schedule resumed the following day. Double dosing is not permitted.

---

Procedural and Population-Specific Use

To ensure proper drug release from the modified-release formulation, the tablet must be swallowed whole with water and must not be chewed, crushed, or opened. Use is generally restricted or requires caution in patients with severe renal impairment (creatinine clearance <30 mL/min) or severe hepatic impairment due to potential changes in drug exposure. The fixed-dose combination is generally intended for long-term management of chronic symptoms.

Research evidence / Overview of studies

Overview of Clinical Research

Urizia is a fixed-dose combination (FDC) therapy containing solifenacin (an antimuscarinic) and tamsulosin (an alpha-blocker). Research has investigated how this combination affects lower urinary tract symptoms (LUTS) in men, particularly those with mixed storage and voiding symptoms associated with benign prostatic hyperplasia (BPH) who had an inadequate response to monotherapy.

Study 1: Evaluation of Pain Scores

Clinical trials have primarily focused on the efficacy of Urizia's components. Solifenacin, evaluated in large randomized controlled trials (RCTs) for overactive bladder (OAB), showed a greater reduction in the number of micturitions and incontinence episodes per 24 hours compared to placebo. A key finding is that studies examined the time-to-onset of effect compared to other treatments.

• Endpoint: The trials assessed the difference in urinary frequency, urgency, and urge incontinence.
• Results: Patients receiving the treatment experienced a change in symptom scores, though evidence remains limited to the short-term window of the original studies. Further research is required to understand long-term outcomes.
• Conclusions: Study investigators suggested that the drug showed a difference in symptom scores compared to placebo in the study population.

Study 2: Combination Therapy Evaluation

Studies in this area evaluated the association between the combination therapy (FDC) and patient outcomes. The NEPTUNE study, an RCT, demonstrated that men with LUTS had a reduction in both voiding and storage symptom scores compared to tamsulosin monotherapy. The trial was observational for some real-world application studies.

• Focus: The study examined the change in symptom severity using tools like the International Prostate Symptom Score (IPSS) and measures of total urgency and frequency scores (TUFS).
• Findings: The data suggested a correlation between the combination therapy and improved symptom scores. The FDC was also studied for its potential effect on treatment persistence compared to taking the two components separately.

Study 3: Studies in Specific Subgroups

Research explored how the drug affects the rate of disease progression in high-risk patients. This involves assessing endpoints like progression-free survival (PFS) in relevant cohorts. For people with mild symptoms, research assessed the rapidness of the effect on symptoms, although the FDC is indicated for moderate-to-severe symptoms in patients who have not responded adequately to monotherapy.

Key Studies & References

1. Effects of Tamsulosin Combined With Solifenacin on Lower Urinary Tract Symptoms: Evidence From a Systematic Review, Meta-Analysis, and Trial Sequential Analysis of Randomized Controlled Trials
2. Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia (Review Article)

Common questions about Urizia (FAQ)

Q: Can I take this medicine with grapefruit or grapefruit juice?

A: Official drug labels are required to specify known interactions with foods like grapefruit or grapefruit juice. These interactions may affect how Urizia works in your body. Official regulatory information specifies if avoiding the combination entirely or adjusting the dose is required.

Q: Does this medication cause weight gain or weight loss?

A: Changes in weight, including both increases and decreases, are sometimes observed as side effects of medications. This information is drawn from clinical trials and post-marketing reports and is listed in the drug's regulatory documentation under undesirable effects.

Q: Is it safe to crush or chew the tablets/capsules?

A: The official instructions for using Urizia explicitly state the required method of administration. To ensure the drug works as intended, it should only be used exactly as directed in the patient information regarding swallowing, crushing, or dividing the tablet or capsule.

Q: Can this drug be taken by children aged 2-11 years?

A: The approved age ranges for taking Urizia are detailed in the regulatory documents, specifically in the indications and administration sections. If the official labelling does not include this age group, the drug is not approved for use in children aged 2–11 years.

Q: Is this drug effective for my specific condition (e.g., anxiety, migraines)?

A: Urizia is only officially approved for the specific condition or conditions listed in its regulatory indication statement. The official regulatory indication states the condition(s) for which Urizia has been approved. Using it for any other condition is outside the scope of the approved label.

Q: How soon will I feel the effects of this drug?

A: Official regulatory documents include details on the pharmacokinetics of Urizia, such as the time it takes for the drug to reach its highest concentration in the blood (Tmax). While this data describes how the drug moves through the body, it does not directly predict when an individual patient will start to notice a therapeutic effect.

Q: Is it safe to take this drug long-term?

A: The approved uses for Urizia are based on clinical trials that define the scope and duration of use. Any risks associated with taking the medication for an extended period beyond the approved scope would be detailed in the regulatory documents under warnings and adverse reactions.

Official Storage Requirements

Urizia (solifenacin/tamsulosin) must be stored according to the conditions defined in the official regulatory labeling to maintain its stability. The medicine must be kept at a temperature below 30 C and actively protected from moisture. To meet this requirement, the tablets must remain in their original container and must not be transferred into any other container.

For child safety, it is a mandatory requirement to store the medicine out of the sight and reach of children.

Official Disposal Instructions

Regulatory documents stipulate that unused or expired Urizia must be disposed of according to local requirements. The medicine must not be discarded into the general household waste or disposed of via the wastewater system. Disposal instructions must be followed to ensure protection of the environment.